SELLAS Life Sciences Group, Inc. (SLS)

1.2800 +0.0400 (+3.23%) At close: 04:00PM EDT

SELLAS Life Sciences Group, Inc.

Times Square Tower
Suite 2503 7 Times Square
New York, NY 10036
United States
646 200 5278
https://www.sellaslifesciences.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 16

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Angelos M. Stergiou M.D., ScD h.c.	Founder, President, CEO & Director	921.99k	N/A	1976
Mr. John Thomas Burns CPA	Senior VP & CFO	338.45k	N/A	1985
Ms. Stacy E. Yeung	VP, Associate General Counsel & Head of Compliance	N/A	N/A	N/A
Dr. Dragan Cicic M.D., MBA	Senior Vice President of Clinical Development	466.43k	N/A	1963
Mr. Andrew Elnatan	VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

Corporate governance

SELLAS Life Sciences Group, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.